Intravitreal bevacizumab for posterior capsule neovascularization | Zendy

Mansour Al-Mohaimeed | Zendy; Saeed Al-Gehedan | Zendy; Hassan Al Dhibi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intravitreal bevacizumab for posterior capsule neovascularization

Author(s) -

Mansour Al-Mohaimeed,

Saeed Al-Gehedan,

Hassan Al Dhibi

Publication year - 2010

Publication title -

saudi journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.359

H-Index - 25

eISSN - 2542-6680

pISSN - 1319-4534

DOI - 10.1016/j.sjopt.2010.02.002

Subject(s) - medicine , capsulotomy , bevacizumab , ophthalmology , capsule , neovascularization , posterior capsule opacification , posterior capsulotomy , surgery , visual acuity , phacoemulsification , intraocular lens , chemotherapy , angiogenesis , botany , biology

We report a case of rapid regression of extensive posterior capsule neovascularization in a 67-year-old diabetic male patient, who developed posterior capsule opacity with neovascularization one year post cataract surgery, after a single injection of intravitreal bevacizumab (Avastin) followed by neodymium:YAG capsulotomy. Rapid regression of the posterior capsule neovascularization, and visual improvement was observed 9 days after the intervention. Posterior capsulotomy was performed successfully without bleeding. Prior to posterior capsulotomy, intravitreal bevacizumab can result in rapid and dramatic regression of posterior capsule neovascularization.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research